HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Abroad (travel likely)RecruitingPHASE2

Conditions

Neurofibromatosis 1 · Plexiform Neurofibromas

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Qingfeng Li, M.D.) · dr.liqingfeng@shsmu.edu.cn · 13301990666

Study leads

Hongqi Tian, Ph.D
Study Chair
Shanghai Kechow Pharma, Inc.

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

Neurofibromatosis 1 · Plexiform Neurofibroma

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Los Angeles, United States

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

Neurofibromatosis 1 · Plexiform Neurofibromas

Abroad (travel likely)Recruiting

Washington D.C., United States · Chicago, United States

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

NF1 · Neurofibromatosis · Cutaneous Neurofibroma

Abroad (travel likely)RecruitingPHASE1

Baltimore, United States

Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study

Neurofibromatosis Type 1 · Neurofibroma

Abroad (travel likely)Recruiting

Bethesda, United States